We have designed our technology to overcome current technical shortcomings and help healthcare systems move towards a more cost-effective and sustainable path for disease diagnosis and Biotech companies to identify patients for clinical trials & subsequent treatment.
gMendel® is the only AI cloud-based end-to-end IVD certified technology for accurate, real time & affordable diagnosis of multiple rare diseases & beyond. Moreover, gMendel®’s technology is automated, transcending the need for bioinformatician‘s intervention, reducing the experimental errors & costs. This improves accessibility and has a potential to revolutionize genetic analysis without any change to current health care protocols.
Compared to available technologies, our novel combination of genomics & AI is Better: sensitivity 99% vs. 63%; unclassified reads 6% vs. 24%; Faster: 1520 vs. 138 reads/sec; dual approach to achieving scalability & precision; More affordable: 10x more samples in one flow cell. The performance evaluation filed with the Danish Medicines Agency, Pharmacovigilance & Medical Devices (DKMA) resulted in successful CE mark under EU IVDD, becoming the world’s first IVD certified test for human genetic disorders utilizing long read sequencing.
Currently, the diagnosis of genetic disorders relies on a set of non-accurate conventional techniques such as karyotyping/FISH, chromosomal microarrays (CMA), Sanger sequencing, comparative genome hybridization (CGH) arrays, MLPA- & PCR-based techniques and tandem mass spectrometry.
Today, the diagnosis of Rare Diseases relies on a set of non-accurate conventional techniques as advanced genomic technologies have high cost and complexity.
In addition, advanced technologies such as next generation sequencing and optical genome mapping (OGM) are still characterized by high complexity, high cost and high risk for patients, particularly in the case of Laboratory Developed Tests (LDTs), which are designed, manufactured and used within a single laboratory.
As a result, even after dozens of medical examinations, which take many years, significant number of patients are still misdiagnosed, creating a heavy human, economic and societal burden. There is an apparent unmet clinical need for better, faster and affordable screening/diagnosis of wide range of genetic disorders.
gMendel® is the only AI cloud-based end-to-end IVD certified technology for accurate, real time & affordable diagnosis of multiple rare diseases & beyond. Moreover, gMendel®’s technology is automated, transcending the need for bioinformatician’s intervention, reducing the experimental errors & costs. This improves accessibility and has a potential to revolutionize genetic analysis without any change to current health care protocols.
The gMendel®️ technology is simple, practical & cost effective, and has greater detection capabilities than the available technologies.
